Skip to content
Resources > Reports

The Future of Generative AI: An Analysis of the Leaders, Opportunities, and Threats

The likes of ChatGPT, Stable Diffusion, Dall-E, and Midjourney have awakened the business world to generative AI (genAI). While startups race to build disruptive products and excite investors, incumbents seek to acquire and deploy the right genAI systems to push their business forward.

Goldman Sachs predicts this technology could boost annual global GDP by 7% over the next 10 years. To capitalize on today’s whirlwind of activity—and not fall behind your peers—you must evolve into a genAI strategy owned by the C-suite.

In this report, we take a deep dive into the generative AI market from the perspective of analysts, executives, experts, and journalists so you can quickly get smart on this evolving technology. Download the report now to uncover:

  • The current market size of generative AI and growth forecasts for the next 5-10 years.
  • The key areas of business that will be most heavily and immediately impacted by genAI.
  • The companies leading this AI transformation and the industries most likely to drive adoption.
  • The risks and areas of opportunity of the fast-growing market that investors and business leaders should watch closely.

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.